+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

United States of America (USA) Drug Pricing and Reimbursement Landscape - Thematic Research

  • ID: 5306943
  • Report
  • March 2021
  • Region: United States
  • 44 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 2
United States of America (USA) Drug Pricing and Reimbursement Landscape - Thematic Research

Summary

The US was already grappling with spiraling healthcare expenditure, lack of affordable care, astronomical drug prices, and a high number of uninsured individuals before the devastating COVID-19 pandemic hit, leaving the healthcare system decimated. Later in the year, the US presidential election added another layer of complexity and division, with the candidates battling over many healthcare issues.

Scope
  • This report reviews some of the most important events that occurred in the drug pricing and reimbursement landscape in the US in 2020. This includes initiatives by the Trump Administration, including executive orders related to drug pricing, the Medicare Part D Senior Savings Model for insulin, and the expansion of telehealth services beyond the pandemic.
  • It also assesses the impact of the COVID-19 pandemic on health insurance coverage and premium rates, and looks at the key battlegrounds during the US Election.
  • As the US now has a new President with different healthcare agendas and priorities, as well as the power to overturn many of the Trump Administration’s policies, considerations for the 2021 drug pricing and reimbursement landscape have also been included.
Reasons to Buy
  • Get an overview of Trump Administration drug pricing policies, including the Medicare Part D Senior Savings Model for insulin. See the status of executive orders issued by the Administration in 2020, including any ongoing lawsuits.
  • Understand how the COVID-19 pandemic impacted insurance coverage, insurance rates, and access to telemedicine in the US in 2020.
  • Understand the key healthcare battlegrounds during the US Presidential Election in 2020.
  • Get an assessment of the potential impact of the Trump Administration drug pricing policies in 2021 and beyond.
  • See how President Biden can shape the US drug pricing and reimbursement landscape in the US, particularly in areas such as the Affordable Care Act.
Note: Product cover images may vary from those shown
2 of 2
US Drug Pricing Landscape 2020
  • Trump Administration Drug Pricing Policies
  • Medicare Part D Senior Savings Model for Insulin
  • Lowering Drug Prices by Putting America First
  • Access to Affordable Life-Saving Medications
  • Lowering Prices for Patients by Eliminating Kickbacks to Middlemen
  • Increasing Drug Importation to Lower Prices for American Patients
  • Drug Pricing and Gouging Continued Across the Industry in 2020
  • Drug Pricing Influencer
COVID-19
  • Impact of COVID-19 on Insurance Coverage
  • Loss of Employer-Sponsored Insurance Coverage During the Pandemic
  • Expansion of the Affordable Care Act to Lower the Number of Uninsured Individuals
  • Impact of COVID-19 on Insurance Premiums
  • Increased Access to Telemedicine During the Pandemic
  • Telemedicine Before the COVID-19 Pandemic
  • Changes to Telemedicine Reimbursement Policies During the COVID-19 Pandemic
  • Increased Use of Telemedicine Due to COVID-19
  • Access to Telemedicine in the US After COVID-19
Impact of the 2020 US Presidential Election
  • The Affordable Care Act
  • Drug Pricing Policy
  • Considerations for 2021
  • Drug Pricing and Reimbursement Constraints Expected to Impede Industry Growth in 2021
  • The Trump Administration’s Reforms Will Have Minimal Impact on the Drug Pricing Landscape in 2021
  • Strengthening the ACA Will Be Important in Reducing the High Number of Uninsured Individuals in the US
  • The Impact of COVID-19 on Insurance Premiums Will Not Be Fully Known Until Later in 2021
  • The Future of US Telehealth Looks Promising Under the Biden Administration
Appendix
  • Abbreviations
  • Related Reports
  • Bibliography
  • About the Authors
  • About the Publisher
  • Contact the Publisher
List of Tables
Table 1: International Drug Price Ratios for the Top 15 Medicare Part B Drugs, by 2018 Spend
Table 2: Average Impact of MFN Model on Reimbursements Rates for Oncology Practices
Table 3: Top 10 Oncology Drugs Impacted by the MFN Model
Table 4: Examples of 2021 Premium Rate Changes for Leading Health Insurers
Table 5: New Services Added to the Medicare Telehealth List

List of Figures
Figure 1: The US Spends Twice As Much on Healthcare As Comparable Countries
Figure 2: Timeline of the Trump Administration’s Drug Pricing Proposals 2018–2020
Figure 3: Beneficiaries Could Save Over 65% On Annual Out-of-Pockets Costs for Insulin
Figure 4: Top US Influencer Trends and Post Related to Drug Pricing in 2020
Figure 5: Number of Uninsured and Uninsured Rate Among the Nonelderly Population in the US (2008–2020)
Figure 6: Use of Telehealth Was Increasing Before the Pandemic, but Use Was Low Overall
Figure 7: Timeline of Key Regulatory and Policy Changes Related to Telemedicine in the US
Figure 8: Most Important Healthcare Issues for the US Election and Views on Party Nominee Approach
Figure 9: US Presidential Election Campaign Messages for the ACA
Figure 10: US Presidential Election Campaign Messages for Drug Pricing
Figure 11: Drug Pricing and Reimbursement Constraints Expected to Have the Greatest Impact in 2021
Note: Product cover images may vary from those shown
Adroll
adroll